Cvac

BIOLOGICAL4 trials

Sponsors

Prima BioMed Ltd, Ohio State University

Conditions

Epithelial Ovarian CancerKidney StonesNephrolithiasisPancreatic Carcinoma Stage IPancreatic Carcinoma Stage II

Phase 2

Ovarian Cancer Vaccine for Patients in Remission

CompletedNCT01068509

Prima BioMed LtdEpithelial Ovarian Cancer

Start: 2010-07-31End: 2015-04-30Updated: 2017-05-11

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

TerminatedNCT01521143

Prima BioMed LtdEpithelial Ovarian Cancer

Start: 2012-01-31End: 2015-03-31Updated: 2016-12-14

Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas

WithdrawnNCT02310971

Prima BioMed LtdPancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II

Start: 2015-02-28End: 2015-03-31Updated: 2015-04-03

Unknown Phase

FANS vs CVAC for Medium to Large Stones

Not yet recruitingNCT07514351

Ohio State UniversityKidney Stones, Nephrolithiasis

Start: 2026-06-01End: 2028-12-01Target: 159Updated: 2026-04-07

Related Papers

Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

Journal for ImmunoTherapy of Cancer2016-06-0247 citations

Progression-free survival in ovarian cancer patients in second remission with mucin-1 autologous dendritic cell therapy.

Journal of Clinical Oncology2014-05-2015 citations